NASDAQ:FBLG
FibroBiologics, Inc. Stock News
$11.35
-0.450 (-3.81%)
At Close: May 17, 2024
FibroBiologics Announces 2024 Annual Meeting of Stockholders
04:30pm, Wednesday, 15'th May 2024
HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the de
FibroBiologics Files 2024 First Quarter Report
05:24pm, Tuesday, 14'th May 2024
HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of
FibroBiologics to Present at the BIO International Convention 2024
09:31am, Tuesday, 07'th May 2024
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the de
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
09:31am, Thursday, 11'th Apr 2024
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
09:31am, Thursday, 28'th Mar 2024
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the develo
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
09:31am, Tuesday, 19'th Mar 2024
HOUSTON , March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the deve
FibroBiologics to Present at Advanced Wound Care Summit USA
09:31am, Wednesday, 13'th Mar 2024
HOUSTON , March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the devel
FibroBiologics Appoints Ruben A. Garcia as General Counsel
09:31am, Wednesday, 06'th Mar 2024
HOUSTON , March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the develo
FibroBiologics Files 2023 Form 10-K Annual Report
05:44pm, Thursday, 29'th Feb 2024
HOUSTON , Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the developm
HOUSTON , Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
09:31am, Tuesday, 13'th Feb 2024
HOUSTON , Feb. 13, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chr
FibroBiologics Announces Three United States Patents for Fibroblast Technology
09:31am, Thursday, 08'th Feb 2024
HOUSTON , Feb. 8, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chron
FibroBiologics Announces Three Japanese Patents on Fibroblast Technology
09:31am, Tuesday, 06'th Feb 2024
HOUSTON , Feb. 6, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chron
U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings
06:16am, Sunday, 04'th Feb 2024
Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of th
